FDA panel nixes interferon indication

Reiman, Patty
January 2000
Dermatology Times;Jan2000, Vol. 21 Issue 1, p13
Trade Publication
Focuses on the United States Food and Drug Administration's Oncologic Drugs Advisory Committee's rejection of interferon type Roferon-A for treatment of surgically resected malignant melanoma. Absence of survival advantage in the study; Exclusion of some patients from the trial.


Related Articles

  • Avonex approved for people at "high risk" of MS.  // Inside MS;Jul-Sep2003, Vol. 21 Issue 3, p28 

    Reports that the U.S. Food and Drug Administration (FDA) has approved the labeling of Avonex or interferon beta-1a to cover people considered to be at high risk for developing clinically definite multiple sclerosis (MS). Role played by a study on the effectiveness of Avonex in delaying or...

  • Betaseron approved for secondary-progressive MS.  // Inside MS;Jul-Sep2003, Vol. 21 Issue 3, p29 

    Announces that the U.S. Food and Drug Administration (FDA) has approved revised labeling of Betaseron or interferon beta-1b to extend its use to treat people with relapsing forms of multiple sclerosis (MS). Influence of the clinical trials of Betaseron in people with secondary-progressive MS on...

  • Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma. Raedler, Lisa A. // Journal of Hematology Oncology Pharmacy;2016Specialissue, Vol. 6, p54 

    The article provides information approval of Imlygic (Talimogene Laherparepvec), an oncolytic viral therapy for treatment of Patients with Recurrent Melanoma, by U.S. Food and Drug Administration (FDA).

  • Current management and novel agents for malignant melanoma. Lee, Byung; Mukhi, Nikhil; Liu, Delong // Journal of Hematology & Oncology;2012, Vol. 5 Issue 1, p1 

    Advanced malignant melanoma remains a challenging cancer. Over the past year, there have been 3 agents approved for treatment of melanoma by Food and Drug Administration. These include pegylated interferon alpha- 2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with...

  • FDA panel recommends approval of Schering-Plough's melanoma drug.  // PharmaWatch: Cancer;Nov2009, Vol. 8 Issue 11, p20 

    The article reports on the announcement by U.S.-based healthcare company Schering-Plough Corp. that the Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee recommends approval of its Pegintron, a melanoma drug. It is noted that Pegintron is a form of protein interferon...

  • Nocturnal leg cramp OTCs banned by FDA.  // Drug Topics;9/5/94, Vol. 138 Issue 17, p8 

    Reports that the Food & Drug Administration (FDA) has banned the sale of over-the-counter products for the treatment and/or prevention of nocturnal leg muscle cramps, effective February 22, 1995.

  • The other drug war. Postrel, Virginia I. // Reason;Nov96, Vol. 28 Issue 6, p4 

    Editorial. Comments on the US Food and Drug Administration's (FDA) drug approval policy. Speed of the FDA's drug review and approval procedures; Impact on Americans' ability to benefit from drugs' benefits.

  • FDA wants more Rx safety data.  // Drug Topics;11/7/94, Vol. 138 Issue 21, p7 

    Reports on the requirement for drug manufacturers to submit safety reports to the Food and Drug Administration.

  • Blockbuster generics hit market.  // Drug Topics;1/23/95, Vol. 139 Issue 2, p7 

    Reports on the US Food & Drug Administration's (FDA) approval of 219 generic drug and antibiotic applications in 1994. Approved medicine with branded sales greater than $50 million.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics